In an­oth­er dis­ap­point­ment for in­vestors, FDA slaps down Bio­haven’s re­vised ver­sion of an old ALS drug

Bio­haven is at risk of mak­ing a habit of dis­ap­point­ing its in­vestors.

Late Fri­day the biotech $BHVN re­port­ed that the FDA had re­ject­ed its ap­pli­ca­tion for rilu­zole, an old drug that they had made over in­to a sub­lin­gual for­mu­la­tion that dis­solves un­der the tongue. Ac­cord­ing to Bio­haven, the FDA had a prob­lem with the ac­tive in­gre­di­ent used in a bioe­quiv­a­lence study back in 2017, which they got from the Cana­di­an drug­mak­er Apo­tex.

Apo­tex, though, has been a dis­as­ter ground. The man­u­fac­tur­er vol­un­tar­i­ly yanked the AN­DAs on 31 drugs — in late 2017 — af­ter the FDA came across se­ri­ous man­u­fac­tur­ing de­fi­cien­cies at their plants in In­dia. A few days ago, the FDA made it of­fi­cial.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER